CMLS III $7.25M Settlement Over Misleading Merger Statements and Fiduciary Breaches

CM Life Sciences III Inc. (CMLS III) was a special purpose acquisition company (SPAC), a type of “blank-check” vehicle that raises money in an IPO and later merges with a private target—here, EQRx Inc.—to take it public. A central SPAC investor protection is the right to redeem shares for roughly $10 (plus any interest) before the merger closes, giving stockholders an exit if they dislike the deal. This settlement focuses on investors who held CMLS III Class A shares immediately after the Dec. 14, 2021 redemption deadline, a narrow window when stockholders’ decision to redeem or hold was locked in and disclosures to the market were especially consequential. The lawsuit alleged that CMLS III’s controllers/sponsor and other defendants breached fiduciary duties and issued materially false or misleading statements tied to the merger process, with the practical effect of discouraging redemptions and leaving investors holding shares through a transaction they might otherwise have exited. That matters because, under Delaware fiduciary-duty principles that often govern SPACs, conflicts can be acute: sponsors and insiders may have strong incentives to complete a deal even if public stockholders would prefer redemption, and misleading merger-related communications can distort that choice. Without admitting wrongdoing, defendants agreed to a $7.25 million settlement; payouts are generally geared to non-redeeming holders and vary based on what they did with their shares after the deadline, reflecting the theory that the alleged harm was being induced to forgo redemption and later suffering losses. More broadly, the case fits into a wider wave of SPAC litigation and regulatory scrutiny that has focused on disclosure quality, conflicts of interest, and the fairness of the de-SPAC process. Similar actions have been brought in Delaware’s Court of Chancery and other courts alleging fiduciary breaches around redemption decisions, board/sponsor conflicts, and allegedly incomplete or overly optimistic deal communications. Industry context also includes heightened SEC attention to SPAC disclosures and projections and the general expectation that merger statements not be materially misleading—pressures that, combined with investor losses in many post-merger SPAC stocks, have made SPAC deal communications and redemption-related disclosures a recurring flashpoint in both private litigation and regulatory policy debates